GCDFP-15 blood levels for stratification of risk of breast cancer development in women with active breast gross cystic disease

被引:6
|
作者
Haagensen, DE
Kelly, D
Bodian, CA
机构
[1] METHODIST HOSP, DEPT SURG, SACRAMENTO, CA USA
[2] MT SINAI MED CTR, DEPT BIOMATH SCI, NEW YORK, NY 10029 USA
来源
BREAST | 1997年 / 6卷 / 03期
关键词
D O I
10.1016/S0960-9776(97)90550-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The risk of developing breast cancer has been shown to be elevated in women with breast gross cystic disease (GCD) confirmed by aspiration of breast cyst fluid. The GCDFP-15 protein is a major component protein of breast GCD fluid. The protein is secreted by apocrine metaplastic cells lining micro and gross cysts of the breast. It is also a constituent protein secreted by normal apocrine glandular systems, and it is present in approximately 50% of breast carcinomas. Blood levels of GCDFP-15 are measurable in the low ng/ml range in normal individuals. A proportion of patients with metastatic breast cancer have high circulating blood levels up to 70000 ng/ml. This study evaluated the relationship between blood levels of GCDFP-15 in women with active breast gross cystic disease, demonstrated by breast cyst aspiration, and the risk of breast cancer development. A group of 135 patients who had active breast gross cystic disease demon strated by cyst aspiration, also had a concomitant blood level of GCDFP-15 determined. The patients have been subsequently followed for an average of 10.1 years and assessed for risk of breast cancer development. Twelve of these women have developed breast carcinoma and two have died of unrelated causes. For the 72 women who clinically developed fewer than 10 aspirated cysts, the relative risk of breast cancer was 1.8 if their highest GCDFP-15 plasma level was in a normal range (less than 40 ng/ml) versus a relative risk of 4.2 if the GCDFP-15 plasma level was elevated. This difference was more pronounced for the 63 women in this study with 10 or more total aspirated cysts, where the relative risk for breast cancer development was 2.0 for women with normal range GCDFP-15 plasma levels versus 7.1 for those with elevated plasma levels. Our data indicate that GDCFP-15 blood levels may be useful in identifying groups of women with active breast gross cystic disease who are at increased risk of developing breast cancer.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 50 条
  • [21] GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer
    Ni, Yun-Bi
    Tsang, Julia Y. S.
    Shao, Mu-Min
    Chan, Siu-Ki
    Cheung, Sai-Yin
    Tong, Joanna
    To, Ka-Fai
    Tse, Gary M.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (01) : 25 - 32
  • [22] GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer
    Yun-Bi Ni
    Julia Y. S. Tsang
    Mu-Min Shao
    Siu-Ki Chan
    Sai-Yin Cheung
    Joanna Tong
    Ka-Fai To
    Gary M. Tse
    Breast Cancer Research and Treatment, 2018, 169 : 25 - 32
  • [23] THE HEPATIC RECOGNITION AND CLEARANCE IN THE RAT OF A CIRCULATING BREAST-CANCER ASSOCIATED GLYCOPROTEIN (GCDFP-15)
    THOMAS, P
    HAAGENSEN, DE
    ZAMCHECK, N
    HEPATOLOGY, 1982, 2 (05) : 674 - 674
  • [24] Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast
    Boccardo, F
    Marenghi, C
    Ghione, G
    Pepe, A
    Parodi, S
    Rubagotti, A
    INTERNATIONAL JOURNAL OF CANCER, 2001, 95 (04) : 260 - 265
  • [25] REGULATION OF THE GCDFP-15 RELEASE BY STEROID-HORMONES IN A BREAST-CANCER CELL-LINE
    DEJARDIN, L
    COLLETTE, J
    FRANCHIMONT, P
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1988, 26 (05): : 296 - 296
  • [26] HEPATIC-CLEARANCE AND METABOLISM IN THE RAT OF A HUMAN-BREAST CANCER ASSOCIATED GLYCOPROTEIN (GCDFP-15)
    TOTH, CA
    HAAGENSEN, DE
    DAVIS, S
    ZAMCHECK, N
    THOMAS, P
    BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (02) : 235 - 243
  • [27] BREAST GROSS CYSTIC-DISEASE PROTEIN-15 IN HUMAN-BREAST CANCER IN CULTURE
    MILLER, WR
    SHIVAS, AA
    FRANCHIMONT, P
    HAAGENSEN, DE
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (02): : 223 - 228
  • [28] GATA3, Mammaglobin, and GCDFP-15 Expression in Subtypes of Breast Ductal Carcinoma in African American Women
    Esnakula, A. K.
    Ricks-Santi, L. J.
    Kanaan, Y.
    Naab, T. J.
    MODERN PATHOLOGY, 2014, 27 : 47A - 47A
  • [29] GATA3, Mammaglobin, and GCDFP-15 Expression in Subtypes of Breast Ductal Carcinoma in African American Women
    Esnakula, A. K.
    Ricks-Santi, L. J.
    Kanaan, Y.
    Naab, T. J.
    LABORATORY INVESTIGATION, 2014, 94 : 47A - 47A
  • [30] Comparative and Additive Sensitivities of immunohistochemical Markers of Breast Cancer Using New Monoclonal Antibodies to GCDFP-15 and Mammaglobin
    Shaw, A. J.
    Goldstein, L. C.
    Kandalaft, P. L.
    Wang, H. C.
    Kussick, S. J.
    Gown, A. M.
    MODERN PATHOLOGY, 2009, 22 : 67A - 67A